Top

Journal of Autism and Developmental Disorders

Gepubliceerd in:

01-05-2009 | Original Paper

Trial Design Challenges When Combining Medication and Parent Training in Children with Pervasive Developmental Disorders

Auteurs: Lawrence Scahill, Michael G. Aman, Christopher J. McDougle, L. Eugene Arnold, James T. McCracken, Benjamin Handen, Cynthia Johnson, James Dziura, Eric Butter, Denis Sukhodolsky, Naomi Swiezy, James Mulick, Kimberly Stigler, Karen Bearss, Louise Ritz, Ann Wagner, Benedetto Vitiello

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 5/2009

Abstract

This paper presents the rationale for a 24-week, randomized trial designed to test whether risperidone plus structured parent training would be superior to risperidone only on measures of noncompliance, irritability and adaptive functioning. In this model, medication reduces tantrums, aggression and self-injury; parent training promotes improvement in noncompliance and adaptive functioning. Thus, medication and parent training target related, but separate, outcomes. At week 24, the medication was gradually withdrawn to determine whether subjects in the combined treatment group could be managed on a lower dose or off medication without relapse. Both symptom reduction and functional improvement are important clinical treatment targets. Thus, experimental evidence on the beneficial effects of combining pharmacotherapy and exportable behavioral interventions is needed to guide clinical practice.

vorige artikel Religiosity, Spirituality, and Socioemotional Functioning in Mothers of Children with Autism Spectrum Disorder

volgende artikel The Swedish Version of the Diagnostic Interview for Social and Communication Disorders (DISCO-10). Psychometric Properties

Abikoff, H., Hechtman, L., Klein, R. G., Weiss, G., Fleiss, K., Etcovitch, J., et al. (2004). Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 802–811.PubMedCrossRef

Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 89, 485–491.PubMed

Aman, M. G., Singh, N. N., & Turbott, S. H. (1987). Reliability of the Aberrant Behavior Checklist and the effect of variations in instructions. American Journal of Mental Deficiency, 92, 237–240.PubMed

Barkley, R. A., & Murphy, K. R. (1998). Attention deficit hyperactivity disorder: A clinical workbook (2nd ed.). New York: Guilford.

Borenstein, M., Rothman, H., & Cohen, J. (1997). Power and precision program. New Jersey: Erlbaum.

Brown, E. C., Aman, M. G., & Havercamp, S. M. (2002). Factor analysis and norms for parent ratings on the Aberrant Behavior Checklist-community for young people in special education. Research in Developmental Disabilities, 23, 45–60.PubMedCrossRef

Campbell, M., Armenteros, J. L., Malone, R. P., Adams, P. B., Eisenberg, Z. W., & Overall, J. E. (1997). Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 835–843.PubMedCrossRef

Carter, A. S., Volkmar, F. R., Sparrow, S. S., Wang, J. J., Lord, C., Dawson, G., et al. (1998). The Vineland Adaptive Behavior Scales: Supplementary norms for individuals with autism. Journal of Autism and Developmental Disorders, 28, 287–302.PubMedCrossRef

National Research Council. (2001). Educating children with autism. Washington, DC: National Academies Press.

Fombonne, E. (2003). The prevalence of autism. Journal of the American Medical Association, 289, 87–89.PubMedCrossRef

Gadow, K. D., Devincent, C. J., Pomeroy, J., & Azizian, A. (2005). Comparison of DSM-IV symptoms in elementary school-age children with PDD versus clinic and community samples. Autism, 9(4), 392–415.PubMedCrossRef

Gibbons, R. D., Hedeker, D., Elkin, I., Waternaux, C., Kraemer, H. C., Greenhouse, J. B., et al. (1993). Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of depression collaborative research program dataset. Archives of General Psychiatry, 50, 739–750.PubMed

Guy, W. (1976). ECDEU assessment manual for psychopharmacology. Washington, DC: DHEW, NIMH.

Hollander, E., Phillips, A., Chaplin, W., Zagursky, K., Novotny, S., Wasserman, S., et al. (2005). A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology, 30, 582–589.PubMedCrossRef

Johnson, C. R., Handen, B. L., Butter, E., Wagner, A., Mulick, J., Sukhodolsky, D. G., et al. (2007). Development of a parent training program for children with pervasive developmental disorders. Behavioral Interventions, 22, 201–221.CrossRef

Kane, J. M., Carson, W. H., Saha, A. R., McQuade, R. D., Ingenito, G. G., Zimbroff, D. L., et al. (2002). Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry, 63, 763–771.PubMed

Kazdin, A., & Weisz, J. R. (Eds.). (2003). Evidence-based psychotherapies for children and adolescents. New York: Guilford Press.

Kraijer, D. (2000). Review of adaptive behavior studies in mentally retarded persons with autism/pervasive developmental disorder. Journal of Autism and Developmental Disorders, 30, 39–47.PubMedCrossRef

Lord, C., Wagner, A., Rogers, S., Szatmari, P., Aman, M., Charman, T., et al. (2005). Challenges in evaluating psychosocial interventions for autistic spectrum disorders. Journal of Autism and Developmental Disorders, 35, 695–708. (discussion 709–711).PubMedCrossRef

Lovaas, O. I. (1987). Behavioral treatment and normal educational and intellectual functioning in young autistic children. Journal of Consulting and Clinical Psychology, 55, 3–9.PubMedCrossRef

McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., Davies, M., et al. (2005). Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. American Journal of Psychiatry, 162, 1142–1148.PubMedCrossRef

McDougle, C. J., Stigler, K. A., Erickson, C. A., & Posey, D. J. (2008). Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. Journal of Clinical Psychiatry, 69(Suppl 4), 15–20.PubMed

MTA Cooperative Group. (1999). Multimodal treatment study of children with ADHD: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 56, 1073–1086.CrossRef

Pediatric OCD Treatment Study (POTS) Team. (2004). Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The Pediatric OCD Treatment Study (POTS) randomized controlled trial. Journal of the American Medical Association, 292, 1969–1976.CrossRef

Research Units on Pediatric Psychopharmacology Autism Network. (2002). Risperidone in children with autism for serious behavioral problems. New England Journal of Medicine, 347, 314–321.CrossRef

Research Units on Pediatric Psychopharmacology Autism Network. (2005a). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62, 1266–1274.CrossRef

Research Units on Pediatric Psychopharmacology Autism Network. (2005b). Risperidone treatment of autistic disorder: Longer term benefits and blinded discontinuation after six months. American Journal of Psychiatry, 162, 1361–1369.CrossRef

Research Units on Pediatric Psychopharmacology Autism Network. (2007). Parent training for children with pervasive developmental disorders: A multi-site feasibility trial. Behavioral Interventions, 22, 179–199.CrossRef

Scahill, L., & Martin, A. (2005). Psychopharmacology. In F. Volkmar, A. Klin, & R. Paul (Eds.), Handbook of autism and pervasive developmental disorders (3rd ed., pp. 1102–1117). New York: Wiley.

Scahill, L., Solanto, M., & McGuire, J. (2008). The science and ethics of placebo in pediatric psychopharmacology. Ethics and Behavior, 18, 266–285.CrossRef

Schreibman, L. (2000). Intensive behavioral/psychoeducational treatments for autism: Research needs and future directions. Journal of Autism and Developmental Disorders, 30, 373–378.PubMedCrossRef

Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., et al. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114(5), 634–641.CrossRef

Shrout, P. E., & Bolger, N. (2002). Mediation in experimental and nonexperimental studies: new procedures and recommendations. Psychological Methods, 7, 422–445.PubMedCrossRef

Smith, T., Buch, G. A., & Gamby, T. E. (2000). Parent-directed, intensive early intervention for children with pervasive developmental disorder. Research in Developmental Disabilities, 21, 297–309.PubMedCrossRef

Smith, T., Scahill, L., Dawson, G., Guthrie, D., Lord, C., Odom, S., et al. (2007). Designing research studies on psychosocial interventions in autism. Journal of Autism and Developmental Disorders, 37, 354–366.PubMedCrossRef

Sparrow, S. S., Balla, D. A., & Cicchetti, D. V. (1984). Vineland Adaptive Behavior scales: Survey form manual. Circle Pines: American Guidance Service.

Treatment for Adolescents with Depression Study (TADS) Team. (2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. Journal of the American Medical Association, 292, 807–820.CrossRef

Williams, S. K., Scahill, L., Vitiello, B., Aman, M. G., Arnold, L. E., McDougle, C. J., et al. (2006). Risperidone and adaptive behavior in children with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 431–439.PubMedCrossRef

Titel: Trial Design Challenges When Combining Medication and Parent Training in Children with Pervasive Developmental Disorders
Auteurs: Lawrence Scahill
Michael G. Aman
Christopher J. McDougle
L. Eugene Arnold
James T. McCracken
Benjamin Handen
Cynthia Johnson
James Dziura
Eric Butter
Denis Sukhodolsky
Naomi Swiezy
James Mulick
Kimberly Stigler
Karen Bearss
Louise Ritz
Ann Wagner
Benedetto Vitiello
Publicatiedatum: 01-05-2009
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 5/2009
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-008-0675-2

Andere artikelen Uitgave 5/2009

Standardizing ADOS Scores for a Measure of Severity in Autism Spectrum Disorders

Original Paper

Bernard Rimland (1928–2006)

Obituary

Trends in US Autism Research Funding

Original Paper

A Double-Blind, Placebo-Controlled Trial of Oral Human Immunoglobulin for Gastrointestinal Dysfunction in Children with Autistic Disorder

Open Access
Original Paper

The Swedish Version of the Diagnostic Interview for Social and Communication Disorders (DISCO-10). Psychometric Properties

Original Paper

JADD Announcements for May 2009

Announcements